A. glehni treatment may additionally ameliorate NAFLD via regulation of SOD, TNFα, 4-HNE, IL6, and ROS (Figures 5, 6, and 10). This evidence concerns the gene SOD1 and metabolic dysfunction-associated steatotic liver disease.